Table 1:

Summary of copy number amplification of AR, MYC and chr8qarm across multiple prostate cancer cohorts with different disease stages

	Primary		Metastatic
Study	TCGA	MSK-IMPACT (Eur Urol 2020)	MSK-IMPACT (CCR2020)	MSK-IMPACT (Eur Urol 2020)	SU2C_(PNAS 2019)
Tissue type	Primary	Primary	mCSPC	metastatic	mCRPC
Sequencing tech	Whole Exom	Targeted-MSKIMPACT	Targeted-MSKIMPACT	Targeted-MSKIMPACT	Whole Exom
Number of samples	492	856	424	432	444
AR-AMP	1.2%	1.1%	4.0%	39.0%	49.0%
MYC-AMP	8.0%	2.9%	7.0%	12.0%	24.0%
chr8q-AMP (mean)	6.5%	2.0%	4.9%	7.3%	20.7%